Trial · NCT06947590
Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy
NCT06947590, Not applicable, Active not recruiting, Xu Liu
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy. Trials, record NCT06947590. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06947590
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy
- NCT number
- NCT06947590
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 78 participants, estimated
- Lead sponsor
- Xu Liu
- Conditions
- HCM - Hypertrophic Cardiomyopathy, Mavacamten
- Interventions
- mavacamten
- First posted
- 2025-04-27
- Last updated
- 2025-04-27
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The change in peak left ventricular outflow tract (LVOT) gradient | From baseline to week 30. | The change in peak left ventricular outflow tract (LVOT) gradient, determined by Doppler echocardiography, during exercise or pharmacologic provocation from baseline to week 30. |
| Secondary | The proportion of patients with a peak left ventricular outflow tract (LVOT) gradient of less than 30 mmHg. | At week 30. | The proportion of patients with a peak left ventricular outflow tract (LVOT) gradient of less than 30 mmHg during exercise or pharmacologic provocation at week 30. |
| Secondary | The proportion of patients with a peak left ventricular outflow tract (LVOT) gradient of less than 50 mmHg. | At week 30. | The proportion of patients with a peak left ventricular outflow tract (LVOT) gradient of less than 50 mmHg during exercise or pharmacologic provocation at week 30. |
| Secondary | The proportion of patients with at least a one-class improvement in NYHA functional classification. | At week 30. | The proportion of patients with at least a one-class improvement in NYHA functional classification at week 30. |
| Secondary | The change in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS). | From baseline to week 30. | The change in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) from baseline to week 30. |
| Secondary | The change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. | From baseline to week 30. | The change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels from baseline to week 30. |
| Secondary | The change in high-sensitivity cardiac troponin I (hs-cTnI) levels. | From baseline to week 30. | The change in high-sensitivity cardiac troponin I (hs-cTnI) levels from baseline to week 30. |
| Secondary | Key safety endpoints | From baseline to week 30. | Key safety endpoints include the incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06947590
GET https://conductscience.org/api/trials/v1/NCT06947590/registered